Precision Immunotherapy in Late-Line mCRC: An Interview with Prof. Sebastian Stintzing on OBERTO-202 at Charité Berlin
By Olesia Karvetskaia, Business Development Manager
April 23, 2026
For patients with metastatic colorectal cancer, the stakes in later treatment lines are painfully high: options narrow, toxicities accumulate, and too many regimens still offer only marginal gains. Yet this is precisely where smarter combinations and better patient selection could be most transformative.
At Charité – Universitätsmedizin Berlin, Professor Sebastian Stintzing is working to push that frontier. As Head of the Department of Hematology, Oncology and Cancer Immunology, his team has spent the past decade building large investigator-initiated trials and a deep translational research program in colorectal cancer, including biomarker-driven analyses across hundreds of patients. That work has helped illuminate which patients are most likely to benefit from which treatments—and why.
Those insights now converge in OBERTO-202, an upcoming investigator-led Phase 2 study in microsatellite-stable metastatic colorectal cancer to be conducted at Charité. The trial combines standard third-line chemotherapy and bevacizumab with an immune checkpoint inhibitor and Treos Bio’s PolyPEPI1018 peptide vaccine. While the vaccine is produced “off the shelf,” it is designed to be personalized in effect: by matching a defined epitope set to each patient’s individual HLA profile, the aim is to reliably trigger robust, multi-epitope immune responses against the tumor.
In this video interview, filmed at Charité in Berlin, Professor Stintzing explains the scientific rationale behind OBERTO-202, how his group uses reverse translational research to refine patient selection, and why a well-tolerated, low-toxicity combination of modern immunotherapy, personalized vaccination, and chemotherapy could offer a much-needed new option for pretreated MSS mCRC patients.
Prof. Sebastian Stintzing, MD
Head of the Department of Hematology, Oncology and Cancer Immunology
Charité – Universitätsmedizin Berlin